Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> MutationCaroline Robert, Paolo A. Ascierto, Georgina V. Long et al.|New England Journal of Medicine|2014Cited by 5.3k
Overall Survival Benefit with Tebentafusp in Metastatic Uveal MelanomaPaul Nathan, Sophie Piperno‐Neumann, April K.S. Salama et al.|New England Journal of Medicine|2021Cited by 869
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumabAlexander M. Menzies, Georgina V. Long, Douglas B. Johnson et al.|Annals of Oncology|2016Cited by 822
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune DisordersDouglas B. Johnson, Joseph I. Clark, Ryan J. Sullivan et al.|JAMA Oncology|2015Cited by 656
Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab TherapyPaolo A. Ascierto, Victoria Atkinson, Georgina V. Long et al.|JAMA Oncology|2018Cited by 345